NEW-LANZOMED

  • Therapeutic Category
    • GASTROINTESTINAL DRUGS
    • ANTIULCER DRUGS
  • Pharmaceutical Form : Film Coated Tablets
  • Composition : Lansoprazole 30 mg /D.R.CAP
  • Active Substance : Lansoprazole

Indications:

* Short-term treatment of active duodenal ulcer.

* Short-term treatment of active benign gastric ulcer.

* Heling of NSAID- associated gastric ulcer.

* Esophagitis due to gastroesophageal reflux.

* Pathological hypersecretory conditions including Zollinger-Ellison syndrome.

Dosage and Administration:

* Duodenal ulcer: One capsule 30 mg daily, for 4 weeks.

* Gastric ulcer: One capsule 30 mg daily, for 8 weeks.

* Esophagitis caused by reflux gastroesophageal: One capsule 30 mg daily, for 4 weeks, it may given an additional 4 weeks of treatment.

* Zollinger-Ellison syndrome (and other pathological hypersecretory condition): Two capsules New-Lanzomed (30 mg x 2) once daily.